EpiCept Corp. has received formal scientific advice from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) that are aligned with the recent guidance given by the U.S. FDA regarding the development of AmiKet, for the treatment of CIPN. EpiCept has reported significant postiive results in the treatment of pain from post-herpetic neuralgia and a positive trend in the treatment of pain in a diabetic neuropathy Phase II study. They will now be designing a Phase III plan, according to Jack Talley, EpiCept President and CEO. READ MORE
Source: GlobeNewswire